AngioDynamics Inc (ANGO) Q3 2026 Earnings Call Transcript

Why It Matters

The shift toward higher‑margin Med Tech products improves profitability and validates AngioDynamics’ strategic transformation, positioning the company for sustained growth in fast‑growing interventional markets.

Key Takeaways

• Revenue $75.7M, +12.2% YoY.
• Med Tech now 47% of sales, up 26% revenue.
• Gross margin improved to 55.3% despite tariff hit.
• Full‑year sales guidance lifted to $308‑$313M.
• Mechanical Thrombectomy team expanded 25% to boost growth.

Pulse Analysis

AngioDynamics’ earnings underscore a decisive pivot from legacy device lines to a portfolio anchored by high‑growth Med Tech platforms. The Auryon atherectomy system, now contributing $16.5 million, illustrates how hospital‑based adoption and international CE‑Mark clearance are expanding the addressable market. By increasing the Med Tech share of revenue to nearly half, the company leverages higher pricing power and better margin profiles, a trend mirrored across the interventional device sector where clinicians favor minimally invasive, office‑based solutions.

The mechanical thrombectomy and NanoKnife businesses are also gaining traction. Mechanical thrombectomy revenue surged 41% as AlphaVac and AngioVac capture market share in pulmonary embolism and venous thrombus treatments, while a dedicated sales force of 50 reps accelerates adoption. NanoKnife’s upcoming CPT I code for prostate cancer promises clearer reimbursement pathways, supporting its 26% revenue lift. Together, these platforms not only diversify AngioDynamics’ revenue streams but also enhance gross margin leverage, offsetting tariff pressures and positioning the firm as a competitive player in high‑margin, procedure‑driven markets.

Financially, the company’s cash balance of $38.8 million and zero‑debt stance provide flexibility for continued R&D investment and potential acquisitions. Raised guidance—sales of $308‑$313 million and adjusted EBITDA of $6‑$10 million—signals management’s confidence in sustaining growth momentum. Investors should monitor the execution of the expanded thrombectomy sales team, international Auryon rollout, and the impact of the NanoKnife reimbursement change, all of which could drive earnings acceleration and improve shareholder returns.